



# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.  
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 27.06.2020

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting

Ref: Our Company's letter dated 17.06.2020

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Saturday, 27.06.2020 at 5:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2020. (Enclosed)
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2020. (Enclosed)

The meeting concluded at 6<sup>00</sup> p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,  
For Concord Drugs Limited

*S. Koni Reddy*

S. Koni Reddy  
Whole-time Director & CFO  
DIN: 02829319




Encl: as above



# CONCORD DRUGS LIMITED

2019/2020 ANNUAL REPORT AND FINANCIAL STATEMENTS





# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana  
Balance sheet as at 31st March 2020

Particulars	Notes	As at March 31, 2020	As at March 31, 2019
<b>ASSETS</b>			
<b>Non-current assets</b>			
(a) Property, plant and equipment	31	993,884	1,100,337
(b) Capital Work-in Progress	32	99,779	28,189
(c) Intangible property	33	88,598	88,100
<b>Financial assets</b>			
(a) Loans & Advances	34	51,616	58,162
(b) Equity securities	35		28,295
<b>Other non-current assets</b>	36	36,293	
<b>Total Non-current Assets</b>		<b>1,269,170</b>	<b>1,403,083</b>
<b>Current Assets</b>			
<b>Inventory</b>	37	1,643,186	1,868,375
<b>Financial assets</b>			
(a) Investments	38		4,898,400
(b) Trade receivables	39	2,544,506	35,880
(c) Cash and cash equivalents	40	1,210	2,581
(d) Trade payables	41	3,478	
(e) Other current assets	42		
<b>Total Current Assets</b>		<b>5,201,280</b>	<b>6,794,256</b>
<b>Total Assets</b>		<b>6,470,450</b>	<b>8,197,339</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
(a) Trade payables	43	3,478	
(b) Other current liabilities	44		
<b>Total Current Liabilities</b>		<b>3,478</b>	<b></b>
<b>Non-current Liabilities</b>			
(a) Long-term debt	45		
(b) Other non-current liabilities	46		
<b>Total Non-current Liabilities</b>		<b></b>	<b></b>
<b>Total Liabilities</b>		<b>3,478</b>	<b></b>
<b>Equity</b>			
(a) Share Capital	47	1,000,000	1,000,000
(b) Reserves	48	5,470,450	7,197,339
<b>Total Equity</b>		<b>6,470,450</b>	<b>8,197,339</b>



# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : [concorddrugsLtd@gmail.com](mailto:concorddrugsLtd@gmail.com)

Website : [www.concorddrugs.in](http://www.concorddrugs.in)

To,

Date: 27.06.2020

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Koni Reddy, Whole-time Director & CFO of Concord Drugs Limited hereby declare that, the statutory Auditors of the company, M/s. NG Rao & Associates Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2020.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,  
For Concord Drugs Limited

*S. Koni Reddy*



S. Koni Reddy  
Whole-time Director & CFO  
DIN: 02829319





**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS**  
**TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED.**

1. We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the three months and year ended March 31, 2020 ('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
2. This statement is the responsibility of the Company's Management and approved by the



We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given

For N.G Rao and Associates  
Chartered Accountants  
FRN:0067985



G Nageswara Rao  
(Partner)

M No:201300

UDIN: 20210304AA41315254

Place: Hyderabad

Date: 27-06-2021